(Image: Associated Press)
November 1, 2019 10:59 AM EDT
R&D

No­vo dumps pro­posed Ry­bel­sus suc­ces­sor for new­er mod­el

Jason Mast

Editor

Bare­ly over a month af­ter gain­ing FDA ap­proval for the first GLP-1 drug Ry­bel­sus, No­vo Nordisk is dump­ing the com­pound it had been de­vel­op­ing …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

FDA ad­comm rais­es risk ques­tions on As­traZeneca’s An­dexxa

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times